-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage from Analysts at StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage from Analysts at StockNews.com
Investment analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Monday. The firm set a "sell" rating on the biotechnology company's stock.
A number of other research analysts have also weighed in on the company. HC Wainwright lowered Genocea Biosciences from a "buy" rating to a "neutral" rating in a report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a report on Friday, April 29th. Finally, Robert W. Baird cut their price objective on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.
Get Genocea Biosciences alerts:Genocea Biosciences Trading Down 6.7 %
Shares of NASDAQ:GNCA opened at $0.01 on Monday. The business's 50-day moving average is $0.03 and its 200 day moving average is $0.56. Genocea Biosciences has a 1 year low of $0.01 and a 1 year high of $2.20. The firm has a market capitalization of $657,820.80, a P/E ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Insider Buying and Selling
In related news, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder Paul Edward Walker sold 5,931,843 shares of the firm's stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $0.07, for a total transaction of $415,229.01. Following the sale, the insider now directly owns 4,445,093 shares of the company's stock, valued at $311,156.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The disclosure for this sale can be found here. Insiders have sold a total of 10,537,612 shares of company stock valued at $781,461 over the last ninety days. Company insiders own 1.61% of the company's stock.Institutional Trading of Genocea Biosciences
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its holdings in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 59.25% of the company's stock.
Genocea Biosciences Company Profile
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Use These To Find Your Stock's Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter's Up For Third Week In A Row: What's Next For The Stock?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Monday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新聞網的投資分析師在週一發佈的一份報告中假設了Genocea Biosciences(納斯達克代碼：GNCA-GET Rating)的股票。該公司對這家生物技術公司的股票設定了“賣出”評級。
A number of other research analysts have also weighed in on the company. HC Wainwright lowered Genocea Biosciences from a "buy" rating to a "neutral" rating in a report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a report on Friday, April 29th. Finally, Robert W. Baird cut their price objective on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.
其他一些研究分析師也加入了對該公司的看法。在4月29日星期五的一份報告中，HC Wainwright將Genocea Biosciences的評級從“買入”下調至“中性”。Stifel Nicolaus在4月29日星期五的一份報告中將Genocea Biosciences的評級從“買入”下調至“持有”。最後，羅伯特·W·貝爾德在4月11日星期一的一份報告中將他們對Genocea Biosciences的目標價格從8.00美元下調至3.00美元。
Genocea Biosciences Trading Down 6.7 %
Genocea Biosciens股價下跌6.7%
Shares of NASDAQ:GNCA opened at $0.01 on Monday. The business's 50-day moving average is $0.03 and its 200 day moving average is $0.56. Genocea Biosciences has a 1 year low of $0.01 and a 1 year high of $2.20. The firm has a market capitalization of $657,820.80, a P/E ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
納斯達克：GNCA的股票週一開盤報0.01美元。該業務的50日移動均線切入位在0.03美元，200日移動均線切入位在0.56美元。Genocea Biosciences的一年低點為0.01美元，一年高位為2.20美元。該公司的市值為657,820.80美元，本益比為-0.02，貝塔係數為2.26。該公司的債務權益比為0.24，流動比率為1.35，速動比率為1.35。
Insider Buying and Selling
內幕買賣
Institutional Trading of Genocea Biosciences
基因生物科學的制度性交易
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its holdings in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 59.25% of the company's stock.
一家機構投資者最近提高了對Genocea Biosciences股票的頭寸。根據不列顛國協股票服務公司向美國證券交易委員會的最新披露，該公司在第四季度增持了基因生物科學公司(納斯達克代碼：GNCA-GET評級)的股票49.4%。該機構投資者在本季度額外購買了10,576股後，持有這家生物技術公司31,981股股票。在最近一次報告期結束時，Federal Equity Services LLC擁有Genocea Biosciences約0.06%的股份，價值3.7萬美元。機構投資者和對沖基金持有該公司59.25%的股票。
Genocea Biosciences Company Profile
Genocea Biosciences公司簡介
(Get Rating)
(獲取評級)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物製藥公司，發現和開發新型癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Use These To Find Your Stock's Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter's Up For Third Week In A Row: What's Next For The Stock?
- 免費獲取StockNews.com關於基因組生物科學的研究報告(GNCA)
- 用這些來找出你的股票的支撐位和阻力位
- 波音股票準備好起飛了嗎？
- 埃隆·馬斯克出局了，但你應該加入推特股票嗎？
- 3個可能令人驚訝的收益公告
- 推特連續第三週上漲：股票的下一步是什麼？
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧